Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

Recruiting now

Conditions studied: Locally Advanced Melanoma

In brief

This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.

Key facts

Study ID

NCT07223411

Run by

John Kirkwood

People needed

20

Starts

2025-11-19

Expected to finish

2031-11-01

Last updated by the study team

2025-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Study participants who meet inclusion criteria for the HCC 24-056 study will be eligible for this study.
• Participants must be willing to provide additional samples beyond what is required of them in HCC 24-056. These include:
• 3 additional tumor biopsies
• 3 additional blood draws
• Participants must have biopsiable non-target disease amenable to at least 3 biopsies.
• Must have the ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Study participants who do not qualify to enroll in the HCC 24-056 study will not be eligible for this study.

Where it is running

• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.